Cardium Therapeutics (CXM) Enters Into Cross-Strategic Equity Investment Partnership with SourceOne Global Partners
Cardium Therapeutics (NYSE: CXM) today announced that it has entered into a cross-strategic investment agreement with SourceOne Global Partners, a leading supplier of exclusive science-based ingredients and proprietary formulas to the nutritional supplement and related functional food & beverage industries. The Cardium and SourceOne agreement provides for the joint development and commercialization of customized nutritional supplements, as well as pharmaceuticals and medical foods based on SourceOne's branded ingredients that include specialized formulations of EPA/DHA Omega-3 oils, Citrus Polymethoxylated Flavonoids, Ubiquinol-QH, TocoSource Palm Tocotrienols, and VESIsorb.
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
Get immediate access to market moving news and alerts with StreetInsider.com Premium - FREE TRIAL!
You May Also Be Interested In
- Dow Chemical (DOW) Wins $2.16B in K-Dow Arbitration
- Coeur d’Alene (CDE) Announces Resumption of Full Production at Palmarejo Mine
- InterDigital (IDCC) Says It Hasn't Seen Huawei Complaint, Can't Offer Response Yet
Create E-mail Alert Related Categories
Corporate NewsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
